Xavier Guillaume - AI Profile | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PO1-18-01: Patient Preferences for HR+/HER2- Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment

Grazia Arpino,Carmine De Angelis,Lorenzo Gerratana,Matteo Lambertini, Sarah Igidbashian, Martina Bellini, Serena Giuntoli,Xavier Guillaume, Julie Behillil,Claire Graziani-Taugeron

Cancer Researchno. 9_Supplement (2024): PO1-18

引用0浏览0引用

Patient Preferences Influencing Treatment Decision-Making in Early-Stage Breast Cancer in Germany, Italy, and Japan

Emuella Flood,Susan McCutcheon,Kathleen Beusterien,deMauri S. Mackie,Stella Mokiou,Xavier Guillaume,Emily Mulvihill

Patient Preference and Adherence (2024): 1517-1530

引用0浏览0WOS引用

Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment

Grazia Arpino, Carmine De Angelis, Lorenzo Gerratana, Matteo Lambertini, Sarah Igidbashian, Martina Bellini, Serena Giuntoli,Xavier Guillaume, Julie Behillil,Claire Graziani-Taugeron

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

Description of Feelings, Perception, and Experience Before and after Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe

Valeria Magarotto,Julien Thevenon,Kate Morgan,Silene ten Seldam,Wafae Iraqi,Xavier Guillaume,Marjorie Leclerc,Claire Graziani-Taugeron,Bleuenn Rault,Dahbia Horchi

Patient Preference and Adherence (2024): 1857-1871

引用0浏览0WOS引用

PB2679: MIXED-METHOD, CROSS-SECTIONAL SURVEY TO DESCRIBE FEELINGS, PERCEPTION, AND EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WHO SWITCHED FROM INTRAVENOUS DARATUMUMAB TO THE SUBCUTANEOUS FORMULATION IN EUROPE

Valeria Magarotto,Julien Thevenon,Kate Morgan,Silene Ten Seldam,Wafae Iraqi,Xavier Guillaume,Dahbia Horchi,Bleuenn Rault, Traugott Ludwig Gruppe

HemaSphereno. S3 (2023)

引用0浏览0引用

Real-world Treatment Patterns of Triple-Class Refractory (TCR) Multiple Myeloma (MM) Across the United States (US), Canada, and Western Europe: A Retrospective Chart Study

Xavier Guillaume,Dahbia Horchi, Jorge Gomez,Patrick Hlavacek,Jinma Ren,Alex Schepart,Didem Aydin,Marco DiBonaventura

Journal of Clinical Oncology（2023）

引用0浏览0引用

Understanding Patient and Physician Perceptions Regarding Treatment-Related Adverse Events in First-Line Chronic Lymphocytic Leukemia (CLL)

Bersabeh Sile,Dahbia Horchi,Bleuenn Rault,Emily Mulvihill,Kathleen Beusterien, Katherine Stewart,Paulo Andre P. Palhares De Miranda,Xavier Guillaume

Bloodno. Supplement 1 (2023): 6546-6546

引用0浏览0引用

Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment

Bersabeh Sile,Dahbia Horchi,Bleuenn Rault,Emily Mulvihill,Kathleen Beusterien,Anna Teschemaker, Katherine Stewart,Paulo Andre P. Palhares De Miranda,Xavier Guillaume

Blood（2023）

引用0浏览0引用

Amy S. Paller,Stephan Weidinger,Korey Capozza,Andrew E. Pink,Mark Tang,Xavier Guillaume,Amy Praestgaard,Marjorie Leclerc,Chien-Chia Chuang,Ryan B. Thomas,Randy Prescilla

Dermatology and Therapy（2023）

引用1浏览0WOS引用

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Michael Wallington,Xavier Guillaume,Emily Mulvihill,Graceanne R. Wayser,Vandana Kaul,Claire Graziani-Taugeron,Mina Shahkarami,Kellie J. Ryan

Blood（2022）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn